{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fasting+arm&page=2", "query": { "intervention": "Fasting arm", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fasting+arm&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-16T05:33:11.780Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02967692", "title": "A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Spartalizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 568, "start_date": "2017-02-17", "completion_date": "2024-08-21", "has_results": true, "last_update_posted_date": "2025-09-18", "last_synced_at": "2026-09-16T05:33:11.780Z", "location_count": 12, "location_summary": "Encinitas, California • Orange, California • San Francisco, California + 9 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02967692" }, { "nct_id": "NCT03434119", "title": "Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine/Lixisenatide", "type": "DRUG" }, { "name": "Insulin glargine (HOE901)", "type": "DRUG" }, { "name": "Background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2018-02-20", "completion_date": "2019-01-07", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-09-16T05:33:11.780Z", "location_count": 85, "location_summary": "Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434119" }, { "nct_id": "NCT03508739", "title": "Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2", "Pre-diabetic", "Hypertension", "Elevated Blood Pressure" ], "interventions": [ { "name": "Sacubitril/Valsartan 200mg (blinded)", "type": "DRUG" }, { "name": "Valsartan 160mg (blinded)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 25, "start_date": "2018-06-01", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-09-16T05:33:11.780Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03508739" }, { "nct_id": "NCT02735044", "title": "Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine,300 U/mL", "type": "DRUG" }, { "name": "Insulin glargine (100 units /mL)", "type": "DRUG" }, { "name": "Background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 463, "start_date": "2016-04-14", "completion_date": "2018-12-20", "has_results": true, "last_update_posted_date": "2022-03-25", "last_synced_at": "2026-09-16T05:33:11.780Z", "location_count": 13, "location_summary": "Tucson, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Buffalo", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02735044" }, { "nct_id": "NCT05357261", "title": "Deliver-EE: Evaluating Effects of Meal Delivery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Wellness Check and Socialization", "type": "BEHAVIORAL" }, { "name": "Prepared Meals", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "66 Years", "maximum_age": null, "sex": "ALL", "summary": "66 Years and older" }, "enrollment_count": 2300, "start_date": "2022-05-01", "completion_date": "2028-03-01", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-09-16T05:33:11.780Z", "location_count": 14, "location_summary": "San Diego, California • Clearwater, Florida • Jacksonville, Florida + 11 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05357261" }, { "nct_id": "NCT04786873", "title": "A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Growth Hormone Deficiency" ], "interventions": [ { "name": "Macimorelin", "type": "DRUG" }, { "name": "Arginine", "type": "DIAGNOSTIC_TEST" }, { "name": "Clonidine", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "AEterna Zentaris", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 101, "start_date": "2021-11-16", "completion_date": "2024-06-13", "has_results": false, "last_update_posted_date": "2024-08-12", "last_synced_at": "2026-09-16T05:33:11.780Z", "location_count": 12, "location_summary": "Tucson, Arizona • Greenwood Village, Colorado • St. Petersburg, Florida + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Greenwood Village", "state": "Colorado" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT04786873" }, { "nct_id": "NCT03512041", "title": "Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy, Young Adults" ], "interventions": [ { "name": "RLIC - 5 cycles", "type": "BEHAVIORAL" }, { "name": "RLIC - 4 Cycles", "type": "BEHAVIORAL" }, { "name": "RLIC - 3 Cycles", "type": "BEHAVIORAL" }, { "name": "Sham conditioning", "type": "BEHAVIORAL" }, { "name": "Balance training", "type": "BEHAVIORAL" }, { "name": "Arm training", "type": "BEHAVIORAL" }, { "name": "Sequence production training", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 40, "start_date": "2016-12-13", "completion_date": "2018-02-13", "has_results": true, "last_update_posted_date": "2019-08-26", "last_synced_at": "2026-09-16T05:33:11.780Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03512041" }, { "nct_id": "NCT01319578", "title": "PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hyperphosphatemia", "Chronic Kidney Disease" ], "interventions": [ { "name": "K2CG chewing gum", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Denver Nephrologists, P.C.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2011-07", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2011-11-15", "last_synced_at": "2026-09-16T05:33:11.780Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01319578" }, { "nct_id": "NCT06782542", "title": "Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "IDH1 Mutation" ], "interventions": [ { "name": "Olutasidenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Justin Watts, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 16, "start_date": "2026-03-31", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-09-16T05:33:11.780Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06782542" }, { "nct_id": "NCT01420094", "title": "Evaluate Onset of Action of a Fast Release Aspirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)", "type": "DRUG" }, { "name": "Acetaminophen (Tylenol extra strength)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "16 Years to 45 Years" }, "enrollment_count": 510, "start_date": "2011-06-16", "completion_date": "2011-09-08", "has_results": false, "last_update_posted_date": "2018-12-19", "last_synced_at": "2026-09-16T05:33:11.780Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01420094" } ] }